Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer
Luis G Paz-Ares, Helen J. Ross, Mary E.R. O'Brien et al. · British Journal of Cancer · 2008
Paclitaxel poliglumex (PPX), a macromolecule drug conjugate linking paclitaxel to polyglutamic acid, reduces systemic exposure to peak concentrations of free paclitaxel. Patients with non-small-cell lung cancer (NSCLC) who had received one prior platinum-based chemotherapy received 175 or 210 mg m(-2) PPX or 75 mg m(-2) docetaxel. The study enrolled 849 previously treated NSCLC patients with advanced disease. Median survival (6.9 months in both arms, hazard ratio=1.09, P=0.257), 1-year survival (PPX=25%, docetaxel=29%, P=0.134), and time to progression (PPX=2 months, docetaxel=2.6 months, P=0.075) were similar between treatment arms. Paclitaxel poliglumex was associated with significantly less grade 3 or 4 neutropenia (P<0.001) and febrile neutropenia (P=0.006). Grade 3 or 4 neuropathy (P<0.001) was more common in the PPX arm. Patients receiving PPX had less alopecia and did not receive routine premedications. More patients discontinued due to adverse events in the PPX arm compared to the docetaxel arm (34 vs 16%, P<0.001). Paclitaxel poliglumex and docetaxel produced similar survival results but had different toxicity profiles. Compared with docetaxel, PPX had less febrile neutropenia and less alopecia, shorter infusion times, and elimination of routine use of medications to prevent hypersensitivity reactions. Paclitaxel poliglumex at a dose of 210 mg m(-2) resulted in increased neurotoxicity compared with docetaxel.
Cited by 171 works. doi:10.1038/sj.bjc.6604372 Open-access PDF
Authors
- Luis G Paz-Ares
- Helen J. Ross
- Mary E.R. O'Brien
- Ulrich Gatzemeier
- Joachim von Pawel
- Eckhard Kaukel
- Lisa Freitag
- W. Digel
- Helge G. Bischoff
- Rosario García‐Campelo
- Nicholas O. Iannotti
- Pavel Reiterer
- Isabel Bover
- J Prendiville
- Amy J. Eisenfeld
- Fred B. Oldham
- B. Bandstra
- Jack W. Singer
- Philip Bonomi
References
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- Cancer Statistics, 2007
- Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
- A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
- Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens
- American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
- Design and analysis of non‐inferiority mortality trials in oncology
- Macromolecular Therapeutics